{"id":50620,"date":"2025-12-13T22:29:11","date_gmt":"2025-12-13T14:29:11","guid":{"rendered":"https:\/\/flcube.com\/?p=50620"},"modified":"2025-12-13T22:29:12","modified_gmt":"2025-12-13T14:29:12","slug":"obt-and-gsk-forge-multi-target-cancer-collaboration-using-ogap-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50620","title":{"rendered":"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Oxford BioTherapeutics (OBT)<\/strong>, a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with <strong>GSK<\/strong> to discover novel, potentially <strong>first\u2011in\u2011class antibody\u2011based therapeutics<\/strong> for cancer treatment. Targets will be identified via OBT\u2019s proprietary <strong>OGAP\u2011Verify discovery platform<\/strong> and validated through joint research, with GSK driving downstream development and commercialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Deal Structure<\/strong><\/td><td>Multi\u2011year, multi\u2011target strategic collaboration<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>OBT\u2019s OGAP\u2011Verify discovery platform<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Novel antibody\u2011based cancer therapeutics<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed (to OBT)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Development, regulatory, and commercial milestones<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales of resulting products<\/td><\/tr><tr><td><strong>Governance<\/strong><\/td><td>Joint research collaboration for target validation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ogap-verify-discovery-platform\">OGAP\u2011Verify Discovery Platform<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Capability<\/strong><\/td><td>Highly sensitive identification of oncology targets with improved drug\u2011development attributes<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Enables creation of differentiated antibody\u2011based therapies<\/td><\/tr><tr><td><strong>Validation<\/strong><\/td><td>Joint research with GSK to confirm target potential<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Supports first\u2011in\u2011class therapeutic development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-responsibilities\">Collaboration Responsibilities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Party<\/th><th>Role<\/th><\/tr><\/thead><tbody><tr><td><strong>Oxford BioTherapeutics<\/strong><\/td><td>Lead target discovery using OGAP\u2011Verify; participate in joint validation research<\/td><\/tr><tr><td><strong>GSK<\/strong><\/td><td>Drive all further research, development, and global commercialization efforts<\/td><\/tr><tr><td><strong>Joint Steering<\/strong><\/td><td>Co\u2011manage target validation phase via joint research collaboration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For OBT:<\/strong> Validates its <strong>AI\u2011powered OGAP platform<\/strong> with a <strong>tier\u2011one pharma partner<\/strong>; provides <strong>non\u2011dilutive funding<\/strong> and long\u2011term royalty potential while maintaining focus on its internal pipeline.<\/li>\n\n\n\n<li><strong>For GSK:<\/strong> Bolsters early\u2011stage oncology pipeline with <strong>novel, validated targets<\/strong> in immuno\u2011oncology and ADC space; leverages OBT\u2019s specialized discovery capabilities to complement internal R&amp;D.<\/li>\n\n\n\n<li><strong>Market Context:<\/strong> Global oncology antibody market exceeds <strong>$120\u202fbillion<\/strong> (2025); first\u2011in\u2011class targets command <strong>premium pricing<\/strong> and reduced competitive pressure.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration\u2019s milestone timelines, target validation success rates, and potential product commercialization. Actual results may differ due to scientific risks, competitive dynamics, and regulatory hurdles.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oxford BioTherapeutics (OBT), a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with GSK&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50621,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[184,3870],"class_list":["post-50620","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-gsk","tag-oxford-biotherapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Oxford BioTherapeutics (OBT), a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with GSK to discover novel, potentially first\u2011in\u2011class antibody\u2011based therapeutics for cancer treatment. Targets will be identified via OBT\u2019s proprietary OGAP\u2011Verify discovery platform and validated through joint research, with GSK driving downstream development and commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50620\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform\" \/>\n<meta property=\"og:description\" content=\"Oxford BioTherapeutics (OBT), a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with GSK to discover novel, potentially first\u2011in\u2011class antibody\u2011based therapeutics for cancer treatment. Targets will be identified via OBT\u2019s proprietary OGAP\u2011Verify discovery platform and validated through joint research, with GSK driving downstream development and commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50620\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-13T14:29:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-13T14:29:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1304.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform\",\"datePublished\":\"2025-12-13T14:29:11+00:00\",\"dateModified\":\"2025-12-13T14:29:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1304.webp\",\"keywords\":[\"GSK\",\"Oxford BioTherapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50620#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50620\",\"name\":\"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1304.webp\",\"datePublished\":\"2025-12-13T14:29:11+00:00\",\"dateModified\":\"2025-12-13T14:29:12+00:00\",\"description\":\"Oxford BioTherapeutics (OBT), a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with GSK to discover novel, potentially first\u2011in\u2011class antibody\u2011based therapeutics for cancer treatment. Targets will be identified via OBT\u2019s proprietary OGAP\u2011Verify discovery platform and validated through joint research, with GSK driving downstream development and commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50620\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1304.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1304.webp\",\"width\":1080,\"height\":608,\"caption\":\"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50620#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Oxford BioTherapeutics (OBT), a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with GSK to discover novel, potentially first\u2011in\u2011class antibody\u2011based therapeutics for cancer treatment. Targets will be identified via OBT\u2019s proprietary OGAP\u2011Verify discovery platform and validated through joint research, with GSK driving downstream development and commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50620","og_locale":"en_US","og_type":"article","og_title":"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform","og_description":"Oxford BioTherapeutics (OBT), a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with GSK to discover novel, potentially first\u2011in\u2011class antibody\u2011based therapeutics for cancer treatment. Targets will be identified via OBT\u2019s proprietary OGAP\u2011Verify discovery platform and validated through joint research, with GSK driving downstream development and commercialization.","og_url":"https:\/\/flcube.com\/?p=50620","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-13T14:29:11+00:00","article_modified_time":"2025-12-13T14:29:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1304.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50620#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50620"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform","datePublished":"2025-12-13T14:29:11+00:00","dateModified":"2025-12-13T14:29:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50620"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50620#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1304.webp","keywords":["GSK","Oxford BioTherapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50620#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50620","url":"https:\/\/flcube.com\/?p=50620","name":"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50620#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50620#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1304.webp","datePublished":"2025-12-13T14:29:11+00:00","dateModified":"2025-12-13T14:29:12+00:00","description":"Oxford BioTherapeutics (OBT), a clinical\u2011stage oncology company, announced a multi\u2011year, multi\u2011target strategic collaboration with GSK to discover novel, potentially first\u2011in\u2011class antibody\u2011based therapeutics for cancer treatment. Targets will be identified via OBT\u2019s proprietary OGAP\u2011Verify discovery platform and validated through joint research, with GSK driving downstream development and commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50620#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50620"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50620#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1304.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1304.webp","width":1080,"height":608,"caption":"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50620#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1304.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50620","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50620"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50620\/revisions"}],"predecessor-version":[{"id":50622,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50620\/revisions\/50622"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50621"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}